Frauenheilkunde up2date, Table of Contents Frauenheilkunde up2date 2016; 10(01): 15-29DOI: 10.1055/s-0041-111473 Allgemeine Gynäkologie und gynäkologische Onkologie Georg Thieme Verlag KG Stuttgart · New YorkOperative Therapie des Ovarialkarzinoms Stefan Kommoss , Veit-Simon Eckle , Ernst Oberlechner , Harald Abele , Bernhard Krämer , Sara Y. BruckerRecommend Article Abstract Buy Article All articles of this category Full Text References Literatur 1 du Bois A, Reuss A, Pujade-Lauraine E et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d Investigateurs Nationaux Pour les Etudes des Cancers de l Ovaire (GINECO). Cancer 2009; 115: 1234-1244 2 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Langversion 1.1.2013, AWMF-Registernummer: 032/035OL.. Im Internet: http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html Stand: 14.12.2015 3 Heitz F, Ognjenovic D, Harter P et al. Abdominal wall metastases in patients with ovarian cancer after laparoscopic surgery: incidence, risk factors, and complications. Int J Gynecol Cancer 2010; 20: 41-46 4 Prat J. FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014; 124: 1-5 5 Trimbos JB. Staging of early ovarian cancer and the impact of lymph node sampling. Int J Gynecol Cancer 2000; 10: 8-11 6 Grabowski JP, Harter P, Buhrmann C et al. Re-operation outcome in patients referred to a gynecologic oncology center with presumed ovarian cancer FIGO I–IIIA after sub-standard initial surgery. Surg Oncol 2012; 21: 31-35 7 Gottschalk A, Poepping DM. Epiduralanästhesie – Epiduralanästhesie in Kombination mit Allgemeinanästhesie. Anasthesiol Intensivmed Notfallmed Schmerzther 2015; 50: 484-493 8 Drexler B, Grasshoff C. Ist tiefe Narkose gefährlich?. Anaesthesist 2012; 61: 678-681 684–685 9 Popping DM, Elia N, Van Aken HK et al. Impact of epidural analgesia on mortality and morbidity after surgery: systematic review and meta-analysis of randomized controlled trials. Ann Surg 2014; 259: 1056-1067 10 Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI). S3 Leitlinie Vermeidung von perioperativer Hypothermie, Langfassung, Version 8, 30.04.2014, AWMF-Registernummer: 001/018.. Im Internet: http://www.awmf.org/leitlinien/detail/ll/001-018.html Stand 14.12.2015 11 Vergote I, Tropé CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-953 12 Schwartz PE, Zheng W. Neoadjuvant chemotherapy for advanced ovarian cancer: the role of cytology in pretreatment diagnosis. Gynecol Oncol 2003; 90: 644-650 13 Kehoe S, Hook J, Nankivell M et al. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC CHORUS trial. Chicago: ASCO Annual Meeting 2013. J Clin Oncol 2013; 31: abstr. 5500 14 Henes M, Neis F, Krämer B et al. Possibilities of fertility preservation in young patients with ovarian cancer. Anticancer Res 2014; 34: 3851-3854 15 Colombo N, Parma G, Lapresa MT et al. Role of conservative surgery in ovarian cancer: the European experience. Int J Gynecol Cancer 2005; 15: 206-211 16 Galaal K, Naik R, Bristow RE et al. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev 2010; (6) CD007822 17 Harter P, du Bois A, Hahmann M et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006; 13: 1702-1710 18 Harter P, Hilpert F, Mahner S et al. Role of cytoreductive surgery in recurrent ovarian cancer. Expert Rev Anticancer Ther 2009; 9: 917-922 19 Harter P, Sehouli J, Reuss A et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 2011; 21: 289-295 20 Königsrainer I, Horvath P, Struller F et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience. Langenbecks Arch Surg 2014; 399: 589-594 21 Königsrainer I, Beckert S, Becker S et al. Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned. Langenbecks Arch Surg 2011; 396: 1077-1081 22 Wallwiener D, Jonat W, Kreienberg R et al. Atlas der gynäkologischen Operationen. 7. Aufl. Stuttgart: Thieme; 2009
